
AI Drug Discovery Firms Draw Capital as Clinical Pipelines Near Market
Biotech companies using computational design platforms are attracting investor capital as AI-generated therapeutics advance toward commercialization in 2026-2027. Wave Life Sciences and other AI-enabled firms report clinical data demonstrating body composition impacts on drug efficacy, while regulatory milestones and cash runway pressures drive M&A consolidation in the sector.


















